Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.82 |
| ▸ | TNF | P01375 | 13/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5905255 | 0.99 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905460 | 0.98 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL844824 | 0.97 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905454 | 0.93 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905181 | 0.91 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905151 | 0.91 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL185853 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL29360102 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL9977552 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905134 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264477-A1 | Methods of using cyclic amides | MULLER GEORGE W | 2006-11-23 | — | — | US | disclosed |
| US-7081464-B2 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050096355-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2005-05-05 | — | — | US | disclosed |
| US-20030114516-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-06-19 | — | — | US | disclosed |
| US-6518281-B2 | Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory | CELGENE CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020002188-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2002-01-03 | — | — | US | disclosed |
| US-6180644-B1 | TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT | CELGENE CORPORATION | 2001-01-30 | — | — | US | disclosed |
| US-5968945-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096355-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | PDE4A 8/4885PDE4B 15/4885PDE4C 12/4885 |
| US-20020002188-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | PDE4A 7/4885PDE4B 13/4885PDE4C 8/4885 |
| US-20030114516-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | PDE4A 7/4885PDE4B 13/4885PDE4C 8/4885 |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | TSLP, STING1, CGAS | PDE4A 8/4885PDE4B 21/4885PDE4C 6/4885 |
| US-20060264477-A1 | Methods of using cyclic amides | RNASE1, RNGTT, CGAS | PDE4A 5/4885PDE4B 10/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.